NYSE:BIOLife Sciences
Is Bio-Rad’s Third Quarter Net Loss and Share Buyback Shaping the Investment Case for BIO?
Bio-Rad Laboratories recently reported third quarter 2025 earnings, with sales of US$653 million and a shift from net income to a net loss of US$341.9 million, alongside an update on its ongoing share repurchase program.
Despite year-to-date sales staying nearly flat, the company's net loss and continued buyback activity stand out as important factors shaping recent investor sentiment.
We'll examine how Bio-Rad's swing to a quarterly net loss and completion of a major share repurchase...